CytomX Therapeutics Inc. (NASDAQ:CTMX) traded down 1.8% during mid-day trading on Monday . The company traded as low as $10.96 and last traded at $11.16, with a volume of 67,716 shares changing hands. The stock had previously closed at $11.37.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 10th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $19.00.

The firm’s market cap is $407.88 million. The firm has a 50 day moving average of $10.22 and a 200-day moving average of $12.00.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Equities research analysts expect that CytomX Therapeutics Inc. will post ($1.59) EPS for the current year.

In other CytomX Therapeutics news, Director Timothy M. Shannon sold 48,427 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $10.07, for a total value of $487,659.89. Following the sale, the director now directly owns 134 shares in the company, valued at approximately $1,349.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ix L.P. Canaan sold 59,621 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $10.80, for a total transaction of $643,906.80. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.